NOTCH1 and B-cell chronic lymphocytic leukemia: Thus, the resistance of NOTCH1-mutated CLL patients to the anti-CD20 rituximab could be likely due to the downregulation of surface CD20 expression by a HDAC-mediated epigenetic mechanism (Figure 2) [126].